Corrigendum: Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics (Review).Molecular medicine reports · 2025
   Review
2. c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance.Frontiers in cell and developmental biology · 2022
   Review
3. Are Integrins Still Practicable Targets for Anti-Cancer Therapy?Cancers · 2019
   Review
4. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.International journal of biological sciences · 2019
   Article
5. The Role of PI3K in Met Driven Cancer: A Recap.Frontiers in molecular biosciences · 2018
   Review

Corrections and comments

• Erratum for
  Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.2016

Authors and funding

17 authors.

Funding

Abstract

PubMed holds no abstract for this paper.